Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors.

Li L, Dutra A, Pak E, Labrie JE 3rd, Gerstein RM, Pandolfi PP, Recht LD, Ross AH.

Neuro Oncol. 2009 Feb;11(1):9-21. doi: 10.1215/15228517-2008-081.

2.

EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.

Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, Pomper MG, Kim J, Laterra J.

Mol Cancer Ther. 2009 Jul;8(7):1751-60. doi: 10.1158/1535-7163.MCT-09-0188.

3.

Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway.

de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, Levy DE, Depinho RA, Bonni A.

Genes Dev. 2008 Feb 15;22(4):449-62. doi: 10.1101/gad.1606508.

4.

Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.

Guillamo JS, de Boüard S, Valable S, Marteau L, Leuraud P, Marie Y, Poupon MF, Parienti JJ, Raymond E, Peschanski M.

Clin Cancer Res. 2009 Jun 1;15(11):3697-704. doi: 10.1158/1078-0432.CCR-08-2042.

5.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79.

PMID:
16854453
7.

Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.

Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, Van Meir EG, Mackman N, Brat DJ.

Cancer Res. 2009 Mar 15;69(6):2540-9. doi: 10.1158/0008-5472.CAN-08-1547.

8.

Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.

Kessler T, Sahm F, Blaes J, Osswald M, Rübmann P, Milford D, Urban S, Jestaedt L, Heiland S, Bendszus M, Hertenstein A, Pfenning PN, Ruiz de Almodóvar C, Wick A, Winkler F, von Deimling A, Platten M, Wick W, Weiler M.

Oncotarget. 2015 Oct 13;6(31):31050-68. doi: 10.18632/oncotarget.2910.

9.

Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway.

Dasari VR, Kaur K, Velpula KK, Gujrati M, Fassett D, Klopfenstein JD, Dinh DH, Rao JS.

PLoS One. 2010 Apr 26;5(4):e10350. doi: 10.1371/journal.pone.0010350.

10.

SCCRO promotes glioma formation and malignant progression in mice.

Broderick SR, Golas BJ, Pham D, Towe CW, Talbot SG, Kaufman A, Bains S, Huryn LA, Yonekawa Y, Carlson D, Hambardzumyan D, Ramanathan Y, Singh B.

Neoplasia. 2010 Jun;12(6):476-84.

11.

Blockade of glioma proliferation through allosteric inhibition of JAK2.

He K, Qi Q, Chan CB, Xiao G, Liu X, Tucker-Burden C, Wang L, Mao H, Lu X, McDonald FE, Luo H, Fan QW, Weiss WA, Sun SY, Brat DJ, Ye K.

Sci Signal. 2013 Jul 9;6(283):ra55. doi: 10.1126/scisignal.2003900.

12.

Alteration of major vault protein in human glioblastoma and its relation with EGFR and PTEN status.

Navarro L, Gil-Benso R, Megías J, Muñoz-Hidalgo L, San-Miguel T, Callaghan RC, González-Darder JM, López-Ginés C, Cerdá-Nicolás MJ.

Neuroscience. 2015 Jun 25;297:243-51. doi: 10.1016/j.neuroscience.2015.04.005.

PMID:
25869624
13.

Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.

Lammering G, Hewit TH, Holmes M, Valerie K, Hawkins W, Lin PS, Mikkelsen RB, Schmidt-Ullrich RK.

Clin Cancer Res. 2004 Oct 1;10(19):6732-43.

14.

MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells.

Yacoub A, Mitchell C, Hong Y, Gopalkrishnan RV, Su ZZ, Gupta P, Sauane M, Lebedeva IV, Curiel DT, Mahasreshti PJ, Rosenfeld MR, Broaddus WC, James CD, Grant S, Fisher PB, Dent P.

Cancer Biol Ther. 2004 Aug;3(8):739-51.

PMID:
15197348
15.

Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.

Cemeus C, Zhao TT, Barrett GM, Lorimer IA, Dimitroulakos J.

J Neurooncol. 2008 Oct;90(1):9-17. doi: 10.1007/s11060-008-9627-0.

PMID:
18566746
16.

High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model.

Wei Q, Clarke L, Scheidenhelm DK, Qian B, Tong A, Sabha N, Karim Z, Bock NA, Reti R, Swoboda R, Purev E, Lavoie JF, Bajenaru ML, Shannon P, Herlyn D, Kaplan D, Henkelman RM, Gutmann DH, Guha A.

Cancer Res. 2006 Aug 1;66(15):7429-37.

17.

Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.

Vitucci M, Karpinich NO, Bash RE, Werneke AM, Schmid RS, White KK, McNeill RS, Huff B, Wang S, Van Dyke T, Miller CR.

Neuro Oncol. 2013 Oct;15(10):1317-29. doi: 10.1093/neuonc/not084.

18.

The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.

Zhan Y, Counelis GJ, O'Rourke DM.

Exp Cell Res. 2009 Aug 15;315(14):2343-57. doi: 10.1016/j.yexcr.2009.05.001.

19.
20.

EGFR signals to mTOR through PKC and independently of Akt in glioma.

Fan QW, Cheng C, Knight ZA, Haas-Kogan D, Stokoe D, James CD, McCormick F, Shokat KM, Weiss WA.

Sci Signal. 2009 Jan 27;2(55):ra4. doi: 10.1126/scisignal.2000014. Erratum in: Sci Signal. 2009;2(60):er4.

Items per page

Supplemental Content

Support Center